SCHEMBL22472879

SCHEMBL22472879

COC(=O)N1C(C)CC(N2CCC(C(=O)NCC(C)C)CC2)CC1C

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
RAB9A P51151 1/20 0.39
HSD17B10 Q99714 1/20 0.37
HCRTR2 O43614 1/20 0.36
KDM4E B2RXH2 1/20 0.36
CYP3A4 P08684 2/20 0.35
USP2 O75604 1/20 0.35
HPGD P15428 1/20 0.35
CHRM1 P11229 1/20 0.35
KMT2A Q03164 1/20 0.35
MTNR1A P48039 3/20 0.34
MTNR1B P49286 3/20 0.34
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22472884 0.90 CHRM1 (0.46) EPHX2SMN1; SMN2LMNAGAARAB9A
SCHEMBL22472877 0.84 SMN1; SMN2 (0.38) EPHX2SMN1; SMN2LMNAGAARAB9A
SCHEMBL22472869 0.83 MAPT (0.45) EPHX2SMN1; SMN2GAAKDM4ECHRM1
SCHEMBL22472937 0.76 CHRM1 (0.55) LMNACHRM1
SCHEMBL21597937 0.75 CHRM1 (0.48) EPHX2SMN1; SMN2USP2HPGDCHRM1
SCHEMBL14978888 0.75 CHRM1 (0.62) SMN1; SMN2LMNAGAAHPGDCHRM1
SCHEMBL22472935 0.74 HPGD (0.47) SMN1; SMN2LMNAHPGDKMT2AALDH1A1
SCHEMBL27176060 0.74 SMN1; SMN2 (0.39) EPHX2SMN1; SMN2LMNAGAARAB9A
SCHEMBL22472885 0.74 CHRM1 (0.47) EPHX2SMN1; SMN2GAAKDM4ECHRM1
SCHEMBL22472938 0.73 PIK3CD (0.46) LMNAHCRTR2CYP3A4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10787447-B2 Pharmaceutical compounds HEPTARES THERAPEUTICS LIMITED (GB) 2020-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10787447-B2 Pharmaceutical compounds CHRM1, CHRM2, CHRM4 EPHX2 1688/4885SMN1; SMN2 2514/4885LMNA 3439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.